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Summary 
 
Continued success in treatment of asthma and COPD requires development of new formulations, which may alter 
spray characteristics and atomisation quality of atomiser devices such as pMDI. Fundamental understanding of 
the underlying physical phenomena and the dynamic nature of pMDI aerosol plumes is essential to maintain pMDI 
device atomisation quality. In this paper, we describe a simulation of pMDI aerosol generation and plume 
development using a model of two-phase flow and atomisation of HFA134/ethanol formulation.  The model is 
implemented within a CFD simulation to study the dynamic aerosol development and predict spray velocity and 
temperature. The CFD result shows plume velocity slows down over a relatively short distance and droplet 
temperature settles at a steady value of 291 K approximately at a distance of 30 mm from the spray orifice. This 
means that droplets reach their final size before reaching the exit of the mouthpiece.  
 
Introduction 
 
pMDI is the most widely used1 aerosol device to treat asthma, but it has one significant drawback, which is the 
high amount of oropharyngeal drug deposition. This deficiency is a function of droplet size and velocity. Evolution 
of these parameters can be addressed by understanding the thermo-fluid dynamic processes governing (i) the 
flow inside the pMDI actuator, (ii) the droplet generation mechanism, and, (iii) the interactions between aerosol 
droplets and inhaled air outside the actuator. These processes determine the characteristics of the dynamic pMDI 
aerosol plume. To the knowledge of these authors there is currently no approach from first principles that is able 
to tackle this problem. This work presents the main features of a pMDI CFD simulation coupled with a model of 
the flow inside the actuator and an atomisation model to produce a well-defined spray source. The development 
of the aerosol plume is tracked along with inhaled air flow through a model of the USP Induction Port (USP-IP). 
 
Internal flow/atomisation model 
 
Flow visualisations using transparent models of pMDI actuator suggest that the dominant two-phase flow regime 
in the actuator sump is a well-mixed, bubbly flow. Our model of the internal flow inside metering and expansion 
chambers assumes such a flow regime. The quasi-steady, homogeneous frozen model (HFM) of Fletcher 2 and 
Clark 3 is used to predict the mass flow rate and velocity through pMDI orifices. The formulation considered here 
is a 90:10 (w/w %) binary mixture of HFA134/ethanol whose saturated vapour pressure is defined in the model 
using an empirical correlation published in reference 4. For the purposes of predicting droplet size, it is assumed 
that the two-phase flow regime inside the spray orifice is predominantly annular, which is supported by flow 
visualisations 5 (see also figure 2 (a)). Using a flat sheet approximation and velocity estimates from the internal 
flow model, within the linear instability sheet atomisation (LISA) 6,7 framework, the growth rate and wavelength of 
the most unstable disturbances on the annular liquid film is estimated using equation 1. 
 
 
𝜔𝜔 = −2𝜈𝜈𝑙𝑙𝑘𝑘2 + �4𝜈𝜈𝑙𝑙2𝑘𝑘4 + Γ𝑉𝑉2𝑘𝑘2 − 𝜎𝜎𝑘𝑘3𝜌𝜌𝑙𝑙  1 
 
where Γ is the density ratio between the gas and liquid phase (i.e. 𝜌𝜌𝑔𝑔/𝜌𝜌𝑙𝑙), 𝜈𝜈𝑙𝑙 and 𝜎𝜎 are the kinematic viscosity and 
surface tension of the liquid and 𝑘𝑘 (=2π/λ) is the wave number. Numerical maximisation of equation 1 with respect 
to wave number yields the maximum growth rate, 𝜔𝜔𝑚𝑚𝑚𝑚𝑚𝑚 as a function of wave number, 𝑘𝑘. The wave number 
corresponding to the maximum growth rate is denoted by 𝐾𝐾𝑠𝑠. Amplification of unstable waves is responsible for 
sheet disintegration and formation of unstable cylindrical ligaments with diameter of: 
 
 
𝑑𝑑𝑙𝑙𝑙𝑙𝑔𝑔 = 2𝜋𝜋𝐶𝐶𝑙𝑙𝑙𝑙𝑔𝑔𝐾𝐾𝑠𝑠  2 
 
    
Figure 1 (a). High resolution 
 image of flow inside expansion chamber 
Figure 1 (b). Schematic  
of internal flow model 
Figure 1 (c). Schematic of  
frozen flow model inside orifices 
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Figure 2 (a). High resolution image of flow inside spray orifice  Figure 2 (b). Schematic of atomisation model 
 
 
where 𝐶𝐶𝑙𝑙𝑙𝑙𝑔𝑔 is ligament constant, which takes a value of 0.5. The diameter of the therapeutic droplets, 𝐷𝐷𝑑𝑑 can be 
obtained based on capillary instability analysis of the initial ligaments 6:  
 
 
𝐷𝐷𝑑𝑑 = 1.88𝑑𝑑𝑙𝑙𝑙𝑙𝑔𝑔 �1 + 3�𝜇𝜇𝑙𝑙2/(𝜌𝜌𝑙𝑙 𝜎𝜎𝑑𝑑𝑙𝑙𝑙𝑙𝑔𝑔 )�1/6 3 
  
 
Previous implementation of such internal flow and atomisation models to pMDIs showed good agreement with 
PDA measurement of spray velocity and droplet size, conducted in near-orifice regions 7,10. 
 
External flow model 
 
The physical problem involves the injection of a pMDI into a standard USP-IP accompanied by ambient co-flow of 
30 l/min, induced by a vacuum pump. Due to evaporation of formulation inside the pMDI actuator, the emerging 
spray consists of liquid (droplets) and propellant vapour phase. Droplets and spray vapour phase (HFA vapour) 
are introduced by means of a transient aerosol generator - the so-called “pseudo spray source”-, using 
information from the internal flow and atomisation models described earlier. Modelling parameters describing the 
actuator are summarised in table 1. 
 
 
 
Figure 3. Schematic of CFD simulation 
 Device parameters Unit Value 
Metering chamber volume µl 25 
Expansion chamber volume µl 25 
Valve orifice diameter mm 0.7 
Spray orifice diameter mm 0.3 
Spray orifice length mm 0.75 
Formulation composition (w/w %) HFA134 90 ethanol 10 
Ambient temperature °C ≈ 22 
 
Table 1. Actuator modelling parametrs and geometric characteristics 
 
Results 
 
The contours of velocity magnitude along with streamlines of the steady air flow prior to injection of the aerosol 
spray source are shown in figure 4 (a-b), rendered on the symmetry plane through the actuator and USP-IP. The 
air flow enters with a mean velocity of 2.5 m/s and travels through the gaps around the canister down towards the 
stem block where the flow direction sharply changes. Here the flow becomes skewed towards the bottom surface 
of the mouthpiece. Next, the air moves around the stem block and upwards, leading to the formation of a complex 
three dimensional flow motion as shown by the visualisation of flow streamlines in figure 4 (b).  This rapid change 
in flow direction accelerates the flow to around 3.5 m/s at the mouthpiece exit plane. Subsequently, the flow 
enters into the converging section of the USP-IP, where recirculation regions appear at the top and bottom 
corners of the USP-IP converged section. After the flow reaches the end of USP-IP horizontal section, another 
rapid change of flow direction occurs, which skews the flow towards the rear wall of the vertical section of the 
USP-IP. The skewed flow profiles near the bottom of the mouthpiece as well as around the outer wall of the  
USP-IP vertical section region cause the creation of pairs of vortices. As shown in figure 4 (c-e), these secondary 
motions can be best visualised in a series of cross-sectional planes perpendicular to the main flow path named 
alphabetically. The velocity magnitude is indicated by colour coding and velocity vectors illustrate secondary flow 
motion. The main features of our flow calculations closely resemble those of reported in 8,9. 
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(a). mid-section and cross-sectional planes (b). Near-orifice region on mid-section plane 
 
Figure 4. (a-b) . Contour of air flow distribution coloured by air flow velocity  
   
(c). Cross-sectional plane (a)  (d). Cross-sectional plane (c) (e). Cross-sectional plane (d) 
 
Figure 4 (c-e) . Contour and vector field of air flow distribution coloured by air flow velocity, on cross-sectional planes 
 
 
The next phase of simulation includes spray injection into the stabilised air flow field. Temporal evolution of spray 
location is shown in the time-ordered images of figure 5 (a-d), which are all rendered on the symmetry plane of 
the pMDI actuator and the USP-IP. The droplets are coloured based on their magnitudes of velocity and are 
superimposed on the contour of gas phase velocity. Early stages of the plume spatial development include the 
formation of a shield-like particle embedded configuration at 0.01 s after the actuation. This flow structure appears 
at the plume tip (indicated by means of a red arrow), is due to the plume front edge experiencing the largest drag 
force; the droplets at the front are pushed away by the more energetic droplets emerging from the upstream 
source. During the first 0.01 s, the plume direction appears to be diverted upwards where deflection is indicated 
by red arrow with dashed tail. This is due to the influence of air flow mean direction (see figure 4 (b)) on droplet 
trajectory, at the initial stages of actuation when the mass loading of the droplets is still small. From 0.03 s 
onwards, however, the mass loading of the droplets has become more significant and the spray source 
overwhelms the inhaled air flow and follows the injection axis. At 0.03 s, and 0.05 s, strong recirculation regions 
are generated as a consequence of air entrainment at the plume edges. At 0.03 s the droplets at the plume tip are 
carried by this recirculation zone and travel backwards through the inlet region of the USP-IP. The spray pattern is 
relatively similar at 0.05 s and 0.07 s. At these times the plume front has progressed into the vertical section of the 
USP-IP where the majority of droplets are pushed towards the outer wall (indicated by arrows in figure 5 (c-d)). 
This is due to the high inertia of the droplets, as well as the air/propellant vapour mixture forcing the flow outwards 
through the 90o◦ bend. At any instant during the injection, it can be seen that the plume slows down to around 1 
m/s over almost 45-50 mm of travelling distance, indicating the large momentum transfer between the spray and 
the air. 
 
 
 
 
Figure 5 (a-d) Contour of gas flow and droplet velocity inside USP-IP 
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Figure 6. (a-d) Contour of gas flow  
and droplet temperature inside USP-IP 
 
Figure 7. Evolution of sampled droplets temperature  
with respect to droplet travelling distance inside USP-IP 
 
Figure 6 (a-d) show droplet temperatures in combination with gas phase temperature rendered on the symmetry 
plane. The plume temperature starts with a prescribed temperature around 250 K, corresponding to normal 
boiling point of multicomponent droplets at atmospheric pressure. As the injection starts, it can be seen that a 
pulse of colder vapour travels through the USP-IP and gradually mixes with the air. Such interaction results in 
HFA vapour/air mixture temperature to settle at an approximate value of 291 K. Figure 7, shows the temperature 
of an arbitrary chosen group of droplets as a function of its axial distance travelled, taking the mouthpiece exit 
location as reference. It can be seen that droplet temperature experiences an initial decrease, which corresponds 
to evaporation of remaining HFA134 content of the droplets. The minimum point on the curve corresponds to 13 
mm from the spray orifice (i.e. 7 mm behind the mouthpiece exit) when all HFA134 in droplets is evaporated. 
From this point onwards the ethanol mass fraction of the droplets is larger than 0.95 and, subsequently the 
droplet temperature increases monotonically as until it reaches thermal equilibrium with the surrounding air/HFA 
vapour mixture. The location of this equilibrium state is around 30 mm from spray orifice (i.e. 10 mm outside the 
mouthpiece exit). Such findings suggest that heat and mass transfer to and from the droplets are significant only 
in the near-orifice region. 
 
 
Concluding remarks 
 
This work has shown an overview of a CFD simulation coupled with a model of the flow inside the actuator and an 
atomisation model to evaluate the development of the aerosol plume produced by a pMDI. Flow distributions 
show that the high-momentum of the spray source dominates the flow after 30 ms when sufficient mass of aerosol 
has entered the USP-IP confirming the need for an accurate description of the spray source. Our internal flow 
model and spray source calculations indicates that droplets containing a HFA/ethanol mixture emerge from the 
spray orifice with a typical size range 3-5 µm and that their size rapidly reduces within the mouthpiece region due 
to evaporation of the remaining volatile HFA, as suggested by temperature trace of figure 7. After an axial 
distance of 30 mm from spray orifice the droplets have reached their final size and temperature, and the aerosol 
and air/HFA vapour gas phase carry the droplets towards the USP-IP vertical section and exit face. Such findings 
may indicate that key plume dynamics in terms of interphase phenomena takes place only in near-orifice region. 
Current CFD model of pMDI may be linked with alternative models such as (i) turbulent diffusion of droplets, and  
(ii) droplet-wall impaction, to estimate oropharyngeal deposition on the walls of USP-IP as the first approximation, 
and realistic mouth-throat geometry as the ideal version.   The outcome of this work may also serve as a design 
tool to predict evolution of spray characteristics as a function of device geometry and formulation composition. 
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